The ClockBinaries ticking down — call itview all →
CYTK
aficamten
PDUFA November 14, 2026
--
no votes yet
SMMT
ivonescimab (HARMONi BLA)
Ph3 November 14, 2026
--
no votes yet
CAPR
deramiocel
PDUFA November 22, 2026
--
no votes yet
SNY
venglustat
Ph3 November 25, 2026
--
no votes yet
BBIO
BBP-418
PDUFA November 27, 2026
--
no votes yet
COGT
bezuclastinib
PDUFA November 30, 2026
--
no votes yet
DWTX
Halneuron
Ph2 Nov'26
--
no votes yet
PEPG
PGN-EDODM1
Ph2 Nov'26
--
no votes yet

Public-market balance sheet screen

listed life-science balance sheets. One screen.

Search the screening universe by ticker or company, then sort the capital structure that matters: cash, debt, enterprise value and diluted share count.

Subscribe on Substack Snapshot: Nov 10, 2026
Prices update daily
Full rebuild weekly
listed companies
Cash figures reported
Share counts reported
Live Wire Full wire →
  • Connecting to the wire…

Readout Radar

149 trial readouts expected in the next 90 days

Full catalyst calendar
  • Now - Nov 11, 2026 BMRN BMN 349 Phase 1
  • Now - Nov 17, 2026 CLRB CLR 131 Phase 1
  • Now - Nov 22, 2026 GENB GB-7624 Phase 1
  • Now - Nov 22, 2026 MSLE SAT-3247 Phase 2
  • Now - Nov 23, 2026 NRIX NX-1607 Phase 1
  • Now - Nov 24, 2026 ALKS Olanzapine Phase 3
  • Now - Nov 24, 2026 ARDX Tenapanor 50 MG Phase 3
  • Now - Nov 24, 2026 CYTK CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) Phase 2

Readout Calendar

ClinicalTrials.gov primary-completion estimates plus management-guided timings. Registry windows are directional; guided timings are company-stated.

Primary completion + 6 to 12 weeks

Next 7 days

  • NKTX NKX019 Nov 9–9, 2026
  • ANL AN4005 Nov 1–30, 2026
  • BOLT BDC-4182 Nov 1–30, 2026
  • DWTX Halneuron Nov 1–30, 2026
  • MLTX Sonelokimab Nov 1–30, 2026
  • PEPG PGN-EDODM1 Nov 1–30, 2026
  • REGN cemdisiran Nov 1–30, 2026
  • RXRX REC-4881 Nov 1–30, 2026
No companies match.Adjust the screener or clear all filters.

MethodologyPrices from market data; cash, debt and shares from latest SEC filings. Debt is set to zero only where filings disclose no debt; EV and net cash stay blank when an input is unavailable. “Shares Out” uses basic shares outstanding where available, otherwise the stated basis. True FDSO adds disclosed options, RSUs, warrants and convertible securities to basic shares; each FDSO cell carries its coverage basis. “Mkt Cap × Cash” is market cap divided by cash; it is blank when cash is zero, negative, or unavailable. “FDMC × Net Cash” is FD market cap divided by net cash; it is blank when net cash is zero or an input is unavailable.

Material Events